Oncolys BioPharma Inc. Oncolys BioPharma Inc.

Oncolys BioPharma Inc.

4588

Rank in Stocks #7416
Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research,... Oncolys BioPharma Inc. is a biotechnology firm dedicated to the research, development, manufacturing, sales, and distribution of oncolytic viruses, pharmaceutical drugs, and diagnostic agents for tumors across Japan, other Asian regions, and the United States. Its robust pipeline features Telomelysin (OBP-301), an oncolytic adenovirus, currently in Phase II clinical trials for the treatment of gastric, gastroesophageal junction, head and neck, and esophageal cancers, and in Phase I trials for hepatocellular carcinoma. Other key developments include OBP-702, a telomerase-specific oncolytic adenovirus in preclinical stages for solid tumors; OBP-2011, also preclinical, targeting SARS-CoV-2 infection; OBP-601 (Censavudine), a nucleotide reverse transcriptase inhibitor that has completed Phase IIb clinical trials for HIV; and OBP-801, a histone deacetylase inhibitor, which is in Phase I clinical trials for solid tumors and preclinical assessment for ophthalmic applications. Additionally, the company is advancing TelomeScan (OBP-401 and OBP-1101), a cancer detection drug designed to identify living circulating tumor cells in cancer patients' blood. Oncolys BioPharma also offers diagnostic medications and inspection services. The company boasts various licensing and collaborative agreements with institutions such as Okayama University, Osaka University, Kyoto Prefectural University of Medicine, Kagoshima University, Astellas Pharma Inc., Yale University, Biologics Consulting Group, Inc., Lonza Houston, Inc., Medigen Biotechnology Corp., and Liquid Biotech USA, Inc. Founded in 2004, Oncolys BioPharma Inc. is based in Tokyo, Japan.
Share Price
$44.36
Last synced: 2026-11-19
Market Cap
$1.30B
Change (1 day)
-6.15%
Change (1 year)
586.72%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Oncolys BioPharma Inc. (4588)
EPS as of September 2026 TTM: $-0.35
According to Oncolys BioPharma Inc.'s latest financial reports, its current EPS (TTM) is $-0.35. At the end of 2025 the company had an EPS of $-0.51, a decrease compared to its 2024 EPS of $-0.49.
EPS history for Oncolys BioPharma Inc. from 2012 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-0.35 -32.29%
2025 $-0.51 3.76%
2024 $-0.49 -36.36%
2023 $-0.77 52.72%
2022 $-0.51 -39.05%
2021 $-0.83 -41.16%
2020 $-1.41 133.81%
2019 $-0.60 -36.76%
2018 $-0.95 1.13%
2017 $-0.94 8.98%
2016 $-0.87 11.57%
2015 $-0.78 15.30%
2014 $-0.67 -24.92%
2013 $-0.90 360.33%
2012 $-0.19 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 157.75%
US
$15.66 -4,635.19%
US
$-7.07 1,947.49%
US
$-5.29 1,432.00%
AU
$12.73 -3,787.29%
BE

Questions about Oncolys BioPharma Inc.'s earnings per share (EPS)

What is Oncolys BioPharma Inc.'s earnings per share (EPS)?

Oncolys BioPharma Inc.'s earnings per share (EPS) over the last twelve months is $-0.35, as of Sep 2026.

What was Oncolys BioPharma Inc.'s earnings per share (EPS) in 2025?

In 2025, Oncolys BioPharma Inc.'s earnings per share (EPS) was $-0.51, compared with $-0.49 in 2024.

How has Oncolys BioPharma Inc.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, Oncolys BioPharma Inc.'s earnings per share (EPS) was highest in 2024 ($-0.49) and lowest in 2020 ($-1.41).

How does Oncolys BioPharma Inc.'s earnings per share (EPS) compare with similar companies?

Oncolys BioPharma Inc.'s earnings per share (EPS) ($-0.35) is higher than that of 3 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.